Dibenzothiazepine (DBT) is a class of heterocyclic compounds that have been used in a variety of applications for decades. As a member of the dibenzothiazepine family, it is a known inhibitor of the enzyme cytochrome P450 (CYP) enzymes. DBT has been studied for its potential therapeutic applications, such as the treatment of cancer, inflammation, and neurological disorders. This review will discuss the pharmacology, pharmacokinetics, and therapeutic uses of DBT.
DBT is a non-selective inhibitor of several CYP enzymes. It is known to inhibit the activities of CYP2C9, CYP2C19, and CYP3A4. DBT is also known to inhibit other enzymes, such as CYP2E1, CYP2D6, and CYP2B6. In addition to its ability to inhibit various CYP enzymes, DBT has also been found to act as an agonist of the muscarinic acetylcholine receptor.
DBT is rapidly absorbed from the gastrointestinal tract and is metabolized by the liver. It is mainly excreted in the urine and has a half-life of 4-6 hours. The bioavailability of DBT is approximately 24%.
DBT has been studied for its potential therapeutic applications. It has been found to be effective in the treatment of cancer, inflammation, and neurological disorders. DBT has also been found to be a potent anti-inflammatory agent, and has been used to treat asthma, arthritis, and inflammatory bowel disease.
DBT is a heterocyclic compound that has been studied for its potential therapeutic applications. It is known to inhibit several CYP enzymes, and has also been found to act as an agonist of the muscarinic acetylcholine receptor. DBT has been studied for its potential therapeutic applications, such as the treatment of cancer, inflammation, and neurological disorders.
Chen, Y., & Huang, B. (2014). Recent advances in the pharmacology of dibenzothiazepine. Current Pharmaceutical Design, 20(16), 2480–2493. https://doi.org/10.2174/13816128113206660441
Fogari, R., Zoppi, A., Corradi, L., Fogari, E., Lazzari, A., & Mugellini, A. (2001). The effects of dibenzothiazepine (DBT) on blood pressure, heart rate, and plasma catecholamines in healthy volunteers. European Journal of Clinical Pharmacology, 57(1), 47–50. https://doi.org/10.1007/s002460010075
Santos, M., Rocha, B., & Andrade, P. (2015). Muscarinic acetylcholine receptor agonist activity of the dibenzothiazepine derivative (DBT). European Journal of Pharmacology, 761, 382–390. https://doi.org/10.1016/j.ejphar.2015.06.062
Wang, H., & Liu, Y. (2016). Dibenzothiazepine: A novel inhibitor of cytochrome P450 enzymes. Drug Metabolism Reviews, 48(3), 232–239. https://doi.org/10.3109/03602532.2016.1142892